Elevated serum B‐cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease
- 20 October 2019
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (12) , 1190-1196
Abstract
Patients with dermatomyositis (DM) frequently have myositis‐specific autoantibodies (MSA), which are closely associated with different clinical features. Patients with anti‐aminoacyl‐tRNA synthetase antibody (ARS‐Ab) and anti‐melanoma differentiation‐associated gene 5 (MDA5)‐Ab often have interstitial lung disease (ILD). Recently, anti‐MDA5‐Ab levels have been shown to correlate with disease activity in DM patients. Thus, B cells that are stimulated by excess B‐cell activating factor (BAFF) play an important role in the pathogenesis of DM through auto‐Ab production. In this study, we investigated the role of BAFF in DM patients. We measured the serum BAFF levels in 56 adult DM patients (14 with anti‐ARS‐Ab, 18 with anti‐MDA5‐Ab, seven with anti‐Mi‐2‐Ab and 17 with anti‐transcriptional intermediary factor‐1γ‐Ab) . For a longitudinal study, 130 serum specimens from 10 DM patients with anti‐MDA5‐Ab were analyzed. Serum BAFF levels were significantly higher in DM patients than in healthy controls. DM patients with elevated serum BAFF levels more frequently had ILD. In subgroup analysis, DM patients with anti‐ARS‐Ab and DM patients with anti‐MDA5‐Ab exhibited increased BAFF levels compared with controls, while DM patients with other MSA showed BAFF levels comparable with controls. In the longitudinal study, serum BAFF levels in DM patients with anti‐MDA5‐Ab were decreased after immunosuppressive therapy along with serum levels of anti‐MDA5‐Ab and ferritin, which are biomarkers of disease activity. These results suggest that BAFF plays an important role in the pathogenesis of ILD in DM patients with anti‐ARS and anti‐MDA5‐Ab. Furthermore, serum BAFF level is associated with disease activity in DM patients with anti‐MDA5‐Ab.Keywords
This publication has 37 references indexed in Scilit:
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals of the Rheumatic Diseases, 2012
- Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnnals of the Rheumatic Diseases, 2012
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levelsArthritis & Rheumatism, 2011
- The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective studyJournal of the American Academy of Dermatology, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- RNA helicase encoded by melanoma differentiation–associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung diseaseArthritis & Rheumatism, 2009
- Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR‐ and type‐I IFN‐dependent and ‐independent pathwaysEuropean Journal of Immunology, 2008
- Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis–associated interstitial lung disease are not predictive of disease progressionArthritis & Rheumatism, 2007
- Autoantibodies to a 140‐kd polypeptide, CADM‐140, in Japanese patients with clinically amyopathic dermatomyositisArthritis & Rheumatism, 2005